1. Home
  2. PVLA vs VCEL Comparison

PVLA vs VCEL Comparison

Compare PVLA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$151.21

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$39.75

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVLA
VCEL
Founded
2015
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
PVLA
VCEL
Price
$151.21
$39.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
5
Target Price
$171.87
$57.75
AVG Volume (30 Days)
160.3K
455.8K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
52.62
60.00
EPS
N/A
N/A
Revenue
$42,810,000.00
$276,259,000.00
Revenue This Year
N/A
$19.40
Revenue Next Year
$104,350.18
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
65.28
16.45
52 Week Low
$56.55
$28.95
52 Week High
$161.38
$49.32

Technical Indicators

Market Signals
Indicator
PVLA
VCEL
Relative Strength Index (RSI) 50.36 42.13
Support Level $145.91 $35.32
Resistance Level $151.18 $41.25
Average True Range (ATR) 5.61 1.23
MACD -0.27 0.15
Stochastic Oscillator 51.04 60.63

Price Performance

Historical Comparison
PVLA
VCEL

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: